KOSDAQBiotech & Pharma382150

Oncocross

₩2,875▲ 0.88%2026-11-18 close
Market Cap
₩37.5B
Turnover
₩26,401,990
Volume
9.3K
Shares out.
13.1M
PER
—
PBR
2.7×
EPS
-₩654
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Oncocross: AI platform pivot, still loss-making

Oncocross has moved its focus from in-house drug development to its AI platform, yet operating losses have been reported for four straight years and for five consecutive quarters through Q3 2026, so the pace of revenue growth is the key point to track.

  1. 1

    2025 revenue was KRW 370 million, down 65.4% year on year, while operating loss widened to KRW 8.83 billion.

  2. 2

    Over the last four quarters (Q4 2025 to Q3 2026), net loss attributable to controlling shareholders totaled KRW 8.05 billion, and Q2 2026 (KRW 1.01 billion) was the only quarter in that span with a profit.

  3. 3

    The business has shifted toward the AI platform, and after the absorption merger completed on July 1, 2026, the company holds real-world cancer patient data for about 10,000 people.

  4. 4

    The pancreatic cancer combination candidate OC212e was accepted as an ASCO 2026 abstract, but no commercial revenue from it has been disclosed yet.

  5. 5

    PER cannot be calculated because the last four quarters show net losses, and price-to-book sits at a premium to net assets.

02

Business structure

Oncocross is an AI-based drug development services company whose core platform is RAPTOR AI. ONCO-RAPTOR AI, specialized for anticancer drugs, is used to identify indications and combination therapies, while ONCOfind, an assistive cancer early-detection solution, extends the company into diagnostics.

Revenue has mainly come from drug evaluation services and joint R&D with pharmaceutical companies, and the company attributed the 2025 revenue decline to fewer new drug evaluation service orders.

During the IPO preparation, the company moved priority from developing its own drug pipeline toward the AI platform business. Around a year after listing, it added a mass spectrometer and began generating protein analysis service revenue.

The absorption merger with an unlisted company was completed on July 1, 2026, bringing in about 10 years of real-world cancer patient data covering roughly 10,000 patients, which the company plans to combine with RAPTOR AI 2.0.

The company describes an ecosystem running from data generation to data asset building, AI analysis and commercialization. On the customer side, it is negotiating joint research and platform adoption terms with major domestic pharmaceutical companies, and some projects have reached working-level discussions.

Among domestic AI drug developers, most typically focus on protein structure design before clinical stages, whereas Oncocross seeks new indications for drugs that have already completed preclinical work.

Some peers use cell line data, while the company emphasizes integrated multi-omics data that combines real patient records with DNA, RNA, proteomic and clinical outcome data.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29,180,750-₩2.4B−8104.5%
2025Q4₩100M-₩2.2B−1567.1%
2026Q1₩200M-₩2.5B−1503.2%
2026Q2₩58,122,500-₩2.7B−4642.0%
2026Q3₩90,121,886-₩2.9B−3186.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩200M-₩10B-₩10.2B−6655.3%−217.3%78.9%
2023₩91,524,496-₩6.8B-₩4.2B−7440.6%−25.6%6.7%
2024₩1.1B-₩7B-₩6.5B−649.6%−31.7%10.2%
2025₩400M-₩8.8B-₩8.9B−2383.0%−66.8%116.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue went from KRW 150 million in 2022 to KRW 91.52 million in 2023, down 39.1%, then rose to KRW 1.07 billion in 2024, up 1,071.5%, making 2024 the largest year of the 2022 to 2025 window.

Revenue fell 65.4% to KRW 370 million in 2025, far below the KRW 3.7 billion that the IPO registration statement had projected for that year. Operating loss narrowed from KRW 10 billion in 2022 to KRW 6.81 billion in 2023, then widened to KRW 6.96 billion in 2024 and KRW 8.83 billion in 2025.

The operating margin improved in 2024 to -649.6%, mainly because the revenue base was larger, while the absolute operating loss stayed close to the 2023 level. The margin deteriorated again to -2,383.0% in 2025 as revenue shrank and costs rose.

The company attributed the 2025 decline to fewer new drug evaluation service orders and higher costs for developing multi-omics analysis technology to upgrade its AI platform.

Net loss attributable to controlling shareholders widened from KRW 4.21 billion in 2023 to KRW 6.48 billion in 2024 and KRW 8.93 billion in 2025, and the total net loss reported each year matches these figures.

The debt-to-equity ratio rose from 6.7% in 2023 to 116.5% in 2025, which appears to coincide with the KRW 12.5 billion convertible bond issued in July 2025. Operating cash flow was negative in every year, at -KRW 8.2 billion in 2022, -KRW 4.91 billion in 2023, -KRW 5.52 billion in 2024 and -KRW 7.41 billion in 2025.

Quarterly revenue was KRW 29.18 million in Q3 2025, KRW 141 million in Q4 2025, KRW 167 million in Q1 2026, KRW 58.12 million in Q2 2026 and KRW 90.12 million in Q3 2026, a volatile path. Q3 2026 revenue rose 208.8% from the year-earlier quarter, yet operating loss widened to KRW 2.87 billion in the same quarter.

In Q2 2026, net profit attributable to controlling shareholders was KRW 1.01 billion despite an operating loss of KRW 2.7 billion, a gap that appears to reflect non-operating items, and the breakdown should be checked in the annual report.

05

Industry analysis

The company's chief executive has said that in global biopharma, the value of data and platform companies that make drug development possible is rising faster than that of companies developing drugs themselves. That view matches the company's decision to prioritize its AI platform.

Press coverage in early 2026 described domestic pharmaceutical companies facing a combination of drug price cuts and US tariff concerns, which has pushed them toward overseas expansion.

In February 2026 the company presented a plan to become a gatekeeper for Asian multi-omics data, including a digital biobanking system and autonomous lab-based data production.

Its approach of finding new indications for drugs that have already completed preclinical work differs from the structure-design focus typical of domestic AI drug developers. In January 2026 the company also made a strategic investment in an AI proteomics analysis firm.

Market sensitivity is visible in its history: its first IPO attempt in 2021 received technology-evaluation grades of A and BBB but was not completed as interest rates rose and share prices fell.

Under the technology-special listing route, press coverage noted that such companies typically receive a grace period on the five-year revenue requirement, which keeps near-term delisting risk limited through 2028. For the sector, the open question is whether data-platform contracts can grow into recurring revenue.

06

Outlook

In late March 2026 the company said its AI-derived pancreatic cancer combination therapy OC212e had been accepted as an ASCO 2026 abstract. The study covers patients with locally advanced and metastatic pancreatic cancer and evaluates the combination with standard therapy.

The company said it plans to present the clinical implications in more detail at future conferences. In February 2026, news reported that a US patent for OC-212e had been registered.

At a February 2026 forum, the company set out digital biobanking, autonomous lab-based data production and expansion into new modalities such as ADCs and TPDs as core priorities.

A 2026 amendment to its articles of incorporation added protein analysis, omics data analysis and digital biobank operations to its business purpose.

Using the patient data it secured through the merger, the company says it is negotiating business terms with major domestic pharmaceutical companies and plans follow-up meetings with global pharmaceutical companies.

In February 2026, a report said joint proteomics research with a Japanese national cancer center had reached the final discussion stage. On the financing side, conversion requests for the KRW 7 billion convertible bond issued in January 2026 become possible from February 9, 2027.

07

Valuation

PER
—
PBR
2.7×
ROE
-53.7%
EPS
-₩654
BPS
₩1,124
Dividend per share
₩0

PER cannot be used for comparison because the last four quarters show net losses, so earnings-based multiples do not apply. Price-to-book sits at a premium to net assets, meaning the share price is set above book value.

That premium appears to reflect expectations for the AI platform, data assets and clinical progress rather than current asset value. Total equity at the end of 2025 was KRW 13.4 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 15.6 billion, giving a debt ratio of 116.5%.

Dividend yield is below the industry average, so shareholder returns through dividends play a minimal role. New share issuance is a dilution factor, and the merger issued 850,397 new shares.

Convertible bonds add further share count variability: the 2025 issue has been convertible since July 25, 2026, and the January 2026 issue becomes convertible from February 9, 2027.

At listing, the company set its offer price by comparing its projected earnings with the PER of listed peers, but the offer band was later lowered after its earnings estimates were revised down. How the valuation reads therefore depends on how much credit is given to the business transition.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Data asset now in-house

The July 2026 absorption merger brought in about 10 years of real-world cancer patient data covering roughly 10,000 patients. The company says it is combining this data with multi-omics analysis to upgrade RAPTOR AI 2.0.

Its argument is that a larger data base widens its negotiating position in platform services and joint research with pharmaceutical companies. Business-term talks with domestic pharmaceutical companies are ongoing.

AI-designed candidate reaches clinic

OC212e, a pancreatic cancer combination therapy, was accepted as an ASCO 2026 abstract, highlighting that an AI-derived strategy has moved into a patient clinical study. The company also reported a US patent registration for OC-212e in February 2026.

The company presents the fact that an AI-designed candidate has entered clinical study as evidence for its platform.

Overseas joint research talks widen

A February 2026 report said joint proteomics research with a Japanese national cancer center had reached the final discussion stage. The company said it plans follow-up meetings and business talks with global pharmaceutical companies.

Whether the Asian multi-omics data gateway concept presented in February 2026 turns into actual contracts is the point to confirm.

09

Bear factors

Thin revenue base

Revenue fell 65.4% to KRW 370 million in 2025, far below the KRW 3.7 billion projected in the IPO registration statement. The company cited fewer new drug evaluation service orders as the cause.

The bear argument is that revenue is small relative to the KRW 8.83 billion operating loss, which limits how much profitability can improve from sales growth alone.

Losses persist and widened

Operating losses have been reported for four straight years from 2022 to 2025 and for five consecutive quarters from Q3 2025 through Q3 2026. Q3 2026 operating loss of KRW 2.87 billion was larger than in the year-earlier quarter. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 8.05 billion.

Funding and dilution burden

The company used about KRW 2.56 billion of its own funds in September 2026 to buy back KRW 2.5 billion of the KRW 12.5 billion convertible bond issued in July 2025 before maturity, leaving KRW 10 billion outstanding. It also issued KRW 7 billion in convertible bonds in January 2026. Together with the 850,397 shares issued in the merger, the share count could rise further.

10

Risk factors

Revenue volatility and dependence on orders

Revenue dropped from KRW 1.07 billion in 2024 to KRW 370 million in 2025, and results move sharply with the size of drug evaluation service orders. Quarterly revenue also swung from KRW 58.12 million in Q2 2026 to KRW 90.12 million in Q3 2026. Without steady large contracts, that volatility may persist.

Clinical and licensing uncertainty

OC212e is currently at the conference-abstract stage, and clinical results and licensing contracts are not yet reflected in disclosed earnings. At listing, the company projected revenue centered on its own pipeline and licensing, but after the strategy change its earnings estimates were revised down.

Depending on conference results and whether contracts materialize, the assessment of the platform business could change.

Financing and governance changes

Conversion of convertible bonds and the merger shares could increase the share count, and the debt ratio rose to 116.5% at the end of 2025. Integrating the merged data assets and retaining platform operating staff are additional challenges.

The chief financial officer and chief technology officer were both replaced after listing, and the company is run by co-CEOs.

11

What to watch next

  1. Around late March 2027 (statutory deadline for the annual report)

    The 2026 annual report will confirm full-year revenue and operating loss, including Q4 2026, in audited form. Its non-operating income breakdown should also explain the Q2 2026 profit attributable to controlling shareholders.

  2. From February 9, 2027

    Conversion requests for the KRW 7 billion convertible bond issued in January 2026 become possible. The KRW 10 billion balance of the 2025 bond has been convertible since July 25, 2026, so conversion volume and potential share count growth should be tracked together.

  3. Around mid-May 2027 (statutory deadline for the Q1 2027 report)

    Q1 2027 revenue and operating loss will be disclosed. The points to check are whether the operating loss narrows from the KRW 2.87 billion recorded in Q3 2026 and whether quarterly revenue moves above the KRW 90.12 million level of Q3 2026.

  4. During 2027 (date not yet announced)

    Conference presentation of clinical data for the OC212e pancreatic cancer combination, and whether business contracts with domestic or global pharmaceutical companies are signed. Whether such contracts show up as revenue is the key test of the platform business.

  5. Around 2028

    This is the period when the grace period on the revenue requirement for technology-special listed companies is expected to end. Revenue requirement management may become a challenge from around this point, so the pace of revenue base growth before then should be tracked.

12

Overall view

Oncocross has shifted weight toward its AI drug platform, and the July 2026 absorption merger brought in real-world cancer patient data covering about 10,000 patients.

On disclosed figures, however, 2025 revenue was KRW 370 million and operating loss was KRW 8.83 billion, with losses reported every year from 2022 to 2025.

Operating losses have also been reported for five consecutive quarters from Q3 2025 through Q3 2026, and the Q2 2026 profit attributable to controlling shareholders moved in the opposite direction to operating results.

Bullish points include the data asset, the ASCO 2026 abstract acceptance and overseas joint research talks. Bearish points include the small revenue base, persistent losses and dilution risk from convertible bonds and merger shares.

PER cannot be calculated and price-to-book sits at a premium to net assets, so how the valuation reads depends on how much credit is given to the business transition.

The next checkpoints are full-year revenue and operating loss in the 2026 annual report, conversion activity from February 9, 2027, and the conference presentations and contract status for OC212e. The gap between the 2027 profitability target set at listing and current results is also worth tracking.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. pharm.edaily.co.kr
  3. news.nate.com
  4. mt.co.kr
  5. m.dailypharm.com
  6. topdaily.kr
  7. calculator.io.kr
  8. m.news.nate.com
  9. v.daum.net
  10. oncocross.com
  11. m.news.nate.com
  12. oncocross.com
  13. m.news.nate.com
  14. hankyung.com
  15. biotimes.co.kr
  16. m.news.nate.com
  17. m.medigatenews.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis